Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in Patients with Acute Coronary Syndrome in Poland

[1]  G. Montalescot,et al.  Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina , 2000, PharmacoEconomics.

[2]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[3]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[4]  E. Antman,et al.  Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. , 2002, European heart journal.

[5]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology* , 2002 .

[6]  Grace Investigators,et al.  Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. , 2001, American heart journal.

[7]  R. Califf,et al.  Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. , 2000, Journal of the American College of Cardiology.

[8]  S. Yusuf,et al.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis , 2000, The Lancet.

[9]  E. Antman,et al.  Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions , 2000 .

[10]  R Goeree,et al.  Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? , 2000, American Heart Journal.

[11]  E. Antman,et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. , 1999, Circulation.

[12]  A. Turpie.  Clinical trials of low molecular weight heparins , 1999 .

[13]  M. Cohen,et al.  Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. , 1999, PharmacoEconomics.

[14]  M. Keltai,et al.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). , 1999, European heart journal.

[15]  E. Vicaut,et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. , 1998, Circulation.

[16]  E. Antman,et al.  Low-molecular-weight heparins: an intriguing new twist with profound implications. , 1998, Circulation.

[17]  E. Antman.  TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. , 1998, American heart journal.

[18]  R. Califf,et al.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarc , 1998, Circulation.

[19]  H. Ostermann.  Low molecular weight heparins , 1998, Der Internist.

[20]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[21]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[22]  W. Klein,et al.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) , 1997, Circulation.

[23]  M. Whooley,et al.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. , 1997, JAMA.

[24]  K. Wiklund,et al.  Low-molecular-weight heparin during instability in coronary artery disease , 1996 .

[25]  E. Gurfinkel,et al.  Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. , 1995, Journal of the American College of Cardiology.

[26]  D. Hoppensteadt,et al.  The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low‐molecular‐weight heparin , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[27]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[28]  V. Fuster,et al.  Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. , 1994, Circulation.

[29]  E. Braunwald.  Unstable angina : diagnosis and management , 1994 .

[30]  R. Kronmal,et al.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.

[31]  C. Madden.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[32]  H. Hemker,et al.  The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma , 1989, Thrombosis and Haemostasis.

[33]  H. Hemker,et al.  The Mode of Action of Heparin in Plasma , 1988, Thrombosis and Haemostasis.

[34]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[35]  A. Telford,et al.  TRIAL OF HEPARIN VERSUS ATENOLOL IN PREVENTION OF MYOCARDIAL INFARCTION IN INTERMEDIATE CORONARY SYNDROME , 1981, The Lancet.

[36]  W. Hoyt,et al.  Letter: Suprastriate hemianopia. , 1974, Lancet.

[37]  S. Wessler,et al.  A Guide to Anticoagulant Therapy , 1961, Circulation.